Source:http://linkedlifedata.com/resource/pubmed/id/19286261
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
8-9
|
pubmed:dateCreated |
2009-4-20
|
pubmed:abstractText |
The recent unexpected observation that complement activation helps tumour growth and progression has an important bearing on the future development of cancer nanomedicines for site-specific tumour targeting as these entities are capable of triggering complement. These issues are discussed and suggestions are provided for future design and development of safer and effective cancer nanomedicines.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
1872-9142
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
46
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1571-2
|
pubmed:dateRevised |
2009-6-16
|
pubmed:meshHeading |
pubmed-meshheading:19286261-Cell Growth Processes,
pubmed-meshheading:19286261-Complement System Proteins,
pubmed-meshheading:19286261-Disease Progression,
pubmed-meshheading:19286261-Humans,
pubmed-meshheading:19286261-Nanomedicine,
pubmed-meshheading:19286261-Nanotechnology,
pubmed-meshheading:19286261-Neoplasms
|
pubmed:year |
2009
|
pubmed:articleTitle |
Complement-mediated tumour growth: implications for cancer nanotechnology and nanomedicines.
|
pubmed:publicationType |
Letter,
Research Support, Non-U.S. Gov't
|